Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Morin

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
AJR. American Journal of Roentgenology|November 21, 2008
Diagnosing acute appendicitis in adultsMichael J Morin
Mabs|May 22, 2023
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activationJohn P Dowling, Pavel A Nikitin, Fang Shen, et al.
Vaccine: X|May 3, 2021
Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike proteinJillian M DiMuzio, Baron C Heimbach, Raymond J Howanski, et al.
Science Immunology|June 30, 2022
IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2Pavel A Nikitin, Jillian M DiMuzio, John P Dowling, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
AJR. American Journal of Roentgenology|November 21, 2008
Diagnosing acute appendicitis in adultsMichael J Morin
Mabs|May 22, 2023
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activationJohn P Dowling, Pavel A Nikitin, Fang Shen, et al.
Vaccine: X|May 3, 2021
Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike proteinJillian M DiMuzio, Baron C Heimbach, Raymond J Howanski, et al.
Science Immunology|June 30, 2022
IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2Pavel A Nikitin, Jillian M DiMuzio, John P Dowling, et al.
Pageof 1